Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus delbrueckii DM8909
- Development stage
- Phase 4
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Vaginal, Oral
01
Overview
Lactobacillus delbrueckii DM8909 is a specific probiotic bacterial strain belonging to the Lactobacillus genus. It has been studied for its potential therapeutic effects, particularly in the context of vaginal health and bacterial vaginosis. This strain exhibits probiotic properties such as auto-aggregation, hydrophobicity, adhesion to cervical epithelial cells, and survivability under oxidative stress. In vitro studies have shown that L. delbrueckii DM8909 can inhibit the growth and adhesion of Gardnerella vaginalis—a key pathogen in bacterial vaginosis—reduce biofilm formation by G. vaginalis, and modulate host inflammatory responses (e.g., decreasing interleukin-8 expression induced by pathogens or hydrogen peroxide). The antibacterial activity is partly attributed to bacteriocin production (such as plantaricin), which can alter gene expression related to virulence and antimicrobial resistance in target pathogens[1][2].
- Brand names
- Dingjunsheng
- Other names
- lactobacillus + DM8909lactobacillus delbrueckii DM8909
02
Targets
Gardnerella vaginalis biofilm formationTLR9 (Toll-like receptor 9)IL8 (C-X-C Motif Chemokine Ligand 8)
Beyond the preview
Go deeper on lactobacillus delbrueckii DM8909.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus delbrueckii DM8909.